...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Trial

I understand that the Simon 2 stage means that they test a small group first and then look at the results before proceeding with the second larger group. It is like the big flock of hungry penguins standing on the ice floe wondering if their shark nemesis is lurking underneath. A few jump in, to test the waters so to speak. If they pop back up, then the rest jump in and go fishing.

The testing was supposed to commence in April, 2019, about 10 months ago. Has there been any information released or hinted about on how far into Part 1 they are, in terms of numbers treated and results? What numbers should be expected to be treated in part one? How much time must pass before they make a decision on its initial safety or efficacy? Has anyone talked to them about progress or  is nothing being said?

Those 2 graphs are interesting as the drug combo is apparently not that much better than 3694 alone.

Share
New Message
Please login to post a reply